| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.7 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |